{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:18:54Z","timestamp":1790205534393,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T00:00:00Z","timestamp":1513209600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81460560"],"award-info":[{"award-number":["81460560"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Applied Basic Research Program of Yunnan Province","award":["2017FB134"],"award-info":[{"award-number":["2017FB134"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00228-017-2395-z","type":"journal-article","created":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T08:32:50Z","timestamp":1513240370000},"page":"433-442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis"],"prefix":"10.1007","volume":"74","author":[{"given":"Ping","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ke","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Di","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong-Hao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,14]]},"reference":[{"key":"2395_CR1","first-page":"S91","volume":"83","author":"M G\u00f6ttlicher","year":"2004","unstructured":"G\u00f6ttlicher M (2004) Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 83:S91\u2013S92","journal-title":"Ann Hematol"},{"issue":"2","key":"2395_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.pharep.2016.12.003","volume":"69","author":"W Jawie\u0144","year":"2017","unstructured":"Jawie\u0144 W, Wilimowska J, K\u0142ys M, Piekoszewski W (2017) Population pharmacokinetic modelling of valproic acid and its selected metabolites in acute VPA poisoning. Pharmacol Rep 69(2):340\u2013349. https:\/\/doi.org\/10.1016\/j.pharep.2016.12.003","journal-title":"Pharmacol Rep"},{"issue":"5","key":"2395_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/00498258409151426","volume":"14","author":"GR Granneman","year":"1984","unstructured":"Granneman GR, Wang SI, Machinist JM, Kesterson JW (1984) Aspects of the metabolism of valproic acid. Xenobiotica 14(5):375\u2013387. https:\/\/doi.org\/10.3109\/00498258409151426","journal-title":"Xenobiotica"},{"key":"2395_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.eplepsyres.2017.02.015","volume":"132","author":"C Wang","year":"2017","unstructured":"Wang C, Wang P, Yang LP, Pan J, Yang X, Ma HY (2017) Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy. Epilepsy Res 132:64\u201369. https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.02.015","journal-title":"Epilepsy Res"},{"issue":"5","key":"2395_CR5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","volume":"27","author":"Y Guo","year":"2012","unstructured":"Guo Y, Hu C, He X, Qiu F, Zhao L (2012) Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. Drug Metab Pharmacokinet 27(5):536\u2013542. https:\/\/doi.org\/10.2133\/dmpk.DMPK-11-NT-144","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"2395_CR6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0090-9556(25)07335-0","volume":"21","author":"T Ebner","year":"1993","unstructured":"Ebner T, Burchell B (1993) Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab Dispos 21(1):50\u201355","journal-title":"Drug Metab Dispos"},{"key":"2395_CR7","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.12659\/MSM.897626","volume":"22","author":"Z Du","year":"2016","unstructured":"Du Z, Jiao Y, Shi L (2016) Association of UGT2B7 and UGT1A4 polymorphisms with serum concentration of antiepileptic drugs in children. Med Sci Monit 22:4107\u20134113. https:\/\/doi.org\/10.12659\/MSM.897626","journal-title":"Med Sci Monit"},{"issue":"8","key":"2395_CR8","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2217\/pgs.11.64","volume":"12","author":"CC Hung","year":"2011","unstructured":"Hung CC, Ho JL, Chang WL, Tai JJ, Hsieh TJ, Hsieh YW, Liou HH (2011) Association of genetic variants in six candidate genes with valproic acid therapy optimization. Pharmacogenomics 12(8):1107\u20131117. https:\/\/doi.org\/10.2217\/pgs.11.64","journal-title":"Pharmacogenomics"},{"issue":"1","key":"2395_CR9","first-page":"73","volume":"26","author":"BL Coffman","year":"1998","unstructured":"Coffman BL, King CD, Rios GR, Tephly TR (1998) The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y (268) and UGT2B7H (268). Drug Metab Dispos 26(1):73\u201377","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"2395_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.clinbiochem.2006.01.002","volume":"39","author":"K Saito","year":"2006","unstructured":"Saito K, Moriya H, Sawaguchi T, Hayakawa T, Nakahara S, Goto A, Arimura Y, Imai K, Kurosawa N, Owada E, Miyamoto A (2006) Haplotype analysis of UDP-glucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin Biochem 39(3):303\u2013308. https:\/\/doi.org\/10.1016\/j.clinbiochem.2006.01.002","journal-title":"Clin Biochem"},{"issue":"8","key":"2395_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/00008571-200011000-00002","volume":"10","author":"CR Bhasker","year":"2000","unstructured":"Bhasker CR, McKinnon W, Stone A, Lo ACT, Kubota T, Ishizaki T, Miners JO (2000) Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10(8):679\u2013685. https:\/\/doi.org\/10.1097\/00008571-200011000-00002","journal-title":"Pharmacogenetics"},{"key":"2395_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.eplepsyres.2015.04.015","volume":"114","author":"Y Sun","year":"2015","unstructured":"Sun Y, Zhuo W, Lin H et al (2015) The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients. Epilepsy Res 114:78\u201380. https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.04.015","journal-title":"Epilepsy Res"},{"issue":"3","key":"2395_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/FTD.0000000000000271","volume":"38","author":"Q Wang","year":"2016","unstructured":"Wang Q, Zhao L, Liang M, Dong Y, Yun W, Qiu F, Meng H, Guo Y (2016) Effects of UGT2B7 genetic polymorphisms on serum concentrations of valproic acid in Chinese children with epilepsy comedicated with lamotrigine. Ther Drug Monit 38(3):343\u2013349. https:\/\/doi.org\/10.1097\/FTD.0000000000000271","journal-title":"Ther Drug Monit"},{"issue":"10","key":"2395_CR14","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00228-012-1277-7","volume":"68","author":"X Chu","year":"2012","unstructured":"Chu X, Zhang L, Wang G, Zhang S, Zhou J, Hao H (2012) Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. Eur J Clin Pharmacol 68(10):1395\u20131401. https:\/\/doi.org\/10.1007\/s00228-012-1277-7","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2395_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13049-017-0382-0","volume":"25","author":"Y Sun","year":"2017","unstructured":"Sun Y, Yu J, Yuan Q, Wu X, Hu J et al (2017) Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6\/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury. Scand J Trauma Resusc Emerg Med 25(1):85. https:\/\/doi.org\/10.1186\/s13049-017-0382-0","journal-title":"Scand J Trauma Resusc Emerg Med"},{"issue":"11","key":"2395_CR16","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2217\/pgs-2016-0030","volume":"17","author":"Z Wen","year":"2016","unstructured":"Wen Z, Fan S, Du C, Yin T, Zhou B et al (2016) Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients. Pharmacogenomics 17(11):1219\u20131225. https:\/\/doi.org\/10.2217\/pgs-2016-0030","journal-title":"Pharmacogenomics"},{"issue":"9","key":"2395_CR17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"2395_CR18","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/j.1538-7836.2012.04756.x","volume":"10","author":"J Reny","year":"2012","unstructured":"Reny J, Combescure C, Daali Y et al (2012) Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost 10(7):1242\u20131251. https:\/\/doi.org\/10.1111\/j.1538-7836.2012.04756.x","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2395_CR19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2217\/pgs-2016-0014","volume":"17","author":"D Chatzistefanidis","year":"2016","unstructured":"Chatzistefanidis D, Lazaros L, Giaka K, Nakou I, Tzoufi M, Georgiou I, Kyritsis A, Markoula S (2016) UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels. Pharmacogenomics 17(8):827\u2013835. https:\/\/doi.org\/10.2217\/pgs-2016-0014","journal-title":"Pharmacogenomics"},{"issue":"3","key":"2395_CR20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/FTD.0000000000000012","volume":"36","author":"K Inoue","year":"2014","unstructured":"Inoue K, Suzuki E, Yazawa R, Yamamoto Y, Takahashi T, Takahashi Y, Imai K, Koyama S, Inoue Y, Tsuji D, Hayashi H, Itoh K (2014) Influence of uridine diphosphate glucuronosyltransferase 2B7-161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients. Ther Drug Monit 36(3):406\u2013409. https:\/\/doi.org\/10.1097\/FTD.0000000000000012","journal-title":"Ther Drug Monit"},{"issue":"8","key":"2395_CR21","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3969\/j.issn.1672-7347.2013.08.002","volume":"38","author":"H Ma","year":"2013","unstructured":"Ma H, Zhang T, Gong Z, Zhou B, Zou M, Xiao S, Zhu W (2013) Effect of UGT2B7 genetic variants on serum valproic acid concentration. Zhong Nan Da Xue Xue Bao Yi Xue Ban 38(8):766\u2013772. https:\/\/doi.org\/10.3969\/j.issn.1672-7347.2013.08.002","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"17","key":"2395_CR22","first-page":"30241","volume":"S0387-7604","author":"H Zhang","year":"2017","unstructured":"Zhang H, Zhang W, Li Y et al (2017) Correlations between UGT2B7\u22172 gene polymorphisms and plasma concentrations of carbamazepine and valproic acid in epilepsy patients. Brain Dev S0387-7604(17):30241\u201330243","journal-title":"Brain Dev"},{"issue":"3","key":"2395_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1468-1331.2010.03187.x","volume":"18","author":"C Chen","year":"2011","unstructured":"Chen C, Xu T, Chen J, Zhou J, Yan Y, Lu Y, Wu S (2011) Allergy and risk of glioma: a meta-analysis. Eur J Neurol 18(3):387\u2013395. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03187.x","journal-title":"Eur J Neurol"},{"issue":"2","key":"2395_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2165\/00003088-198510020-00003","volume":"10","author":"DW Chadwick","year":"1985","unstructured":"Chadwick DW (1985) Concentration-effect relationships of valproic acid. Clin Pharmacokinet 10(2):155\u2013163. https:\/\/doi.org\/10.2165\/00003088-198510020-00003","journal-title":"Clin Pharmacokinet"},{"key":"2395_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jchromb.2014.08.011","volume":"969","author":"T Huo","year":"2014","unstructured":"Huo T, Chen X, Lu X, Qu L, Liu Y, Cai S (2014) An effective assessment of valproate sodium-induced hepatotoxicity with UPLC-MS and (1)HNMR-based metabonomics approach. J Chromatogr B Analyt Technol Biomed Life Sci 969:109\u2013116. https:\/\/doi.org\/10.1016\/j.jchromb.2014.08.011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2","key":"2395_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/toxsci\/kfl096","volume":"94","author":"TK Kiang","year":"2006","unstructured":"Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK (2006) Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1\/*1 genotype. Toxicol Sci 94(2):261\u2013271. https:\/\/doi.org\/10.1093\/toxsci\/kfl096","journal-title":"Toxicol Sci"},{"issue":"1","key":"2395_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.tpj.6500139","volume":"3","author":"M Holthe","year":"2003","unstructured":"Holthe M, Rakv\u00e5g TN, Klepstad P, Idle JR, Kaasa S, Krokan HE, Skorpen F (2003) Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 3(1):17\u201326. https:\/\/doi.org\/10.1038\/sj.tpj.6500139","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"2395_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.abb.2004.02.004","volume":"424","author":"K Sakaguchi","year":"2004","unstructured":"Sakaguchi K, Green M, Stock N, Reger TS, Zunic J, King C (2004) Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms. Arch Biochem Biophys 424(2):219\u2013225. https:\/\/doi.org\/10.1016\/j.abb.2004.02.004","journal-title":"Arch Biochem Biophys"},{"issue":"8","key":"2395_CR29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/FPC.0b013e3283037fe4","volume":"18","author":"F Innocenti","year":"2008","unstructured":"Innocenti F, Liu W, Fackenthal D, Ram\u00edrez J, Chen PX, Ye X, Wu X, Zhang W, Mirkov S, Das S, Cook E Jr, Ratain MJ (2008) Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics 18(8):683\u2013697. https:\/\/doi.org\/10.1097\/FPC.0b013e3283037fe4","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"2395_CR30","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/sj.clpt.6100324","volume":"83","author":"JY Chung","year":"2008","unstructured":"Chung JY, Cho JY, Yu KS et al (2008) Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther 83(4):595\u2013600. https:\/\/doi.org\/10.1038\/sj.clpt.6100324","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"2395_CR31","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00228-015-1925-9","volume":"71","author":"L Liu","year":"2015","unstructured":"Liu L, Zhao L, Wang Q, Qiu F, Wu X, Ma Y (2015) Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7-161C\u2009>\u2009T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children. Eur J Clin Pharmacol 71(11):1341\u20131347. https:\/\/doi.org\/10.1007\/s00228-015-1925-9","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2395_CR32","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1006\/bbrc.1993.1847","volume":"194","author":"CJ Jin","year":"1993","unstructured":"Jin CJ, Miners JO, Lillywhite KJ, Mackenzie PI (1993) cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily. Biochem Biophys Res Commun 194(1):496\u2013503. https:\/\/doi.org\/10.1006\/bbrc.1993.1847","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"2395_CR33","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S0009-9236(03)00053-5","volume":"73","author":"MB Sawyer","year":"2003","unstructured":"Sawyer MB, Innocenti F, Das S, Cheng C, Ram\u00edrez J, Pantle-Fisher FH, Wright C, Badner J, Pei D, Boyett JM, Cook E Jr, Ratain MJ (2003) A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 73(6):566\u2013574. https:\/\/doi.org\/10.1016\/S0009-9236(03)00053-5","journal-title":"Clin Pharmacol Ther"},{"issue":"2\u20133","key":"2395_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.eplepsyres.2006.04.002","volume":"70","author":"C Fattore","year":"2006","unstructured":"Fattore C, Messina S, Battino D, Croci D, Mamoli D, Perucca E (2006) The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: a case-matched evaluation based on therapeutic drug monitoring data. Epilepsy Res 70(2\u20133):153\u2013160. https:\/\/doi.org\/10.1016\/j.eplepsyres.2006.04.002","journal-title":"Epilepsy Res"},{"issue":"6","key":"2395_CR35","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1365-2125.1984.tb02401.x","volume":"17","author":"E Perucca","year":"1984","unstructured":"Perucca E, Grimaldi R, Gatti G, Pirracchio S, Crema F, Frigo GM (1984) Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol 17(6):665\u2013669. https:\/\/doi.org\/10.1111\/j.1365-2125.1984.tb02401.x","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2395_CR36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2165\/00003088-200847050-00002","volume":"47","author":"JM Butler","year":"2008","unstructured":"Butler JM, Begg EJ (2008) Free drug metabolic clearance in elderly people. Clin Pharmacokinet 47(5):297\u2013321. https:\/\/doi.org\/10.2165\/00003088-200847050-00002","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2395_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/0008-5472.CAN-05-2857","volume":"66","author":"J Thibaudeau","year":"2006","unstructured":"Thibaudeau J, L\u00e9pine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, T\u00eatu B, Jacob S, Perusse L, B\u00e9langer A, Guillemette C (2006) Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 66(1):125\u2013133. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2857","journal-title":"Cancer Res"},{"issue":"1","key":"2395_CR38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pharmthera.2004.10.013","volume":"106","author":"TK Kiang","year":"2005","unstructured":"Kiang TK, Ensom MH, Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106(1):97\u2013132. https:\/\/doi.org\/10.1016\/j.pharmthera.2004.10.013","journal-title":"Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-017-2395-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2395-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2395-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T19:39:09Z","timestamp":1751139549000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-017-2395-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,14]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["2395"],"URL":"https:\/\/doi.org\/10.1007\/s00228-017-2395-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,14]]}}}